Zevra Therapeutics, Inc. ZVRA
11.04
(0.22)
(1.95%)
as of 25 Sep
- Market cap
- $668.7M
- P/E
- 11.6×
Follow ZVRA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 34.33% | 94.80% | 79.85% | 28.11% |
+8 more TTM periods Free account |
|
| 20.57% | 51.85% | 33.52% | 12.36% | ||
ROIC |
0.00% | (65.48%) | (153.83%) | 0.00% | |
Return on Tangible Assets |
28.27% | 63.81% | 42.12% | 14.30% | |
Average Days of Receivables |
60.33 | 65.96 | 79.73 | 72.84 | |
Free Cash Flow per Share |
0.56 | 0.21 | (0.04) | (0.42) | |
Free Cash Flow |
33.07 | 12.49 | (1.98) | (23.71) | |
Capital Expenditures |
(0.33) | (0.28) | (0.39) | (0.35) | |
Piotroski F-Score |
6.00 | 7.00 | 6.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
7.60% | 3.14% | (0.39%) | (5.93%) | |
Accounts Receivable Turnover |
6.68 | 7.05 | 6.31 | 6.85 | |
Accounts Payable Turnover |
0.41 | 1.15 | 0.89 | 0.92 | |
Inventory Turnover |
3.47 | 7.00 | 8.89 | 0.00 | |
Average Days of Payables |
824.62 | 250.45 | 256.84 | 247.51 | |
Days of Inventory on Hand |
144.64 | 49.50 | 38.53 | 30.56 | |
Tax Rate |
(0.16) | (0.07) | (0.04) | (0.34) | |
Research and Development Expense of Revenue |
10.97% | 11.35% | 11.97% | 21.89% | |
Selling, General and Administrative Expense of Revenue |
54.85% | 64.48% | 72.90% | 86.96% | |
Share Based Compensation of Revenue |
9.65% | 10.32% | 11.94% | 14.83% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.58 | 0.11 | (0.02) | (0.82) | |
Depreciation/Fixed assets |
(2.81) | 134.97 | 121.96 | 124.77 | |
Capex/Depreciation |
0.18 | 0.00 | (0.01) | (0.01) | |
Revenue per Share |
2.30 | 2.09 | 1.92 | 1.51 | |
Operating CF per Share |
0.56 | 0.22 | (0.03) | (0.42) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
42.25% | 95.68% | 72.87% | 33.80% |
Columns are period end dates